NCT05878210

Evaluating the SUBLOCADE Treatment Exit Strategy

A Phase IV Study to Evaluate the SUBLOCADE Treatment Exit Strategy

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 12 (actual)
• Sponsor: Indivior Inc. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to observe and assess the successful taper and opioid withdrawal experience after participants stop receiving SUBLOCADE because their healthcare provider determines their disease symptoms have been controlled for at least 9 months and they, together with their healthcare provider, plan to discontinue MOUD.

Detailed description

This is a Phase IV, observational, multicentre, open-label, study in participants with a history of OUD, who have been on SUBLOCADE treatment for at least 12 injections, have had disease symptoms controlled for at least 9 months in the opinion of the healthcare provider, and both healthcare provider and participant plan to discontinue MOUD treatment.

Conditions

• Opioid Use Disorder

Timeline

• Start date: 2023-11-24
• Primary completion: 2025-05-09
• Completion: 2025-05-09
• First posted: 2023-05-26
• Last updated: 2026-01-22

Locations

2 sites across 2 countries: United States, Canada